<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01523054</url>
  </required_header>
  <id_info>
    <org_study_id>SH-MET-0027</org_study_id>
    <nct_id>NCT01523054</nct_id>
  </id_info>
  <brief_title>Metoprolol in Acute Myocardial Infarction. A PK/PD Study</brief_title>
  <official_title>A Pharmacokinetic and Pharmacodynamic Study Comparing Metoprolol IR and Metoprolol CR/XL Subsequent to Initial Treatment With Intravenous and/or Oral Metoprolol in Patients With Suspected Acut Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The objective of the study was to compare treatment with two different oral formulations of
      metoprolol, metoprolol immediate release (IR) and metoprolol extended release (CR/XL) in
      patients with acute myocardial infarction regarding the following:

      Pharmacokinetics, peak and trough plasma concentrations and area under the plasma
      concentration curve.

      Pharmacodynamics, hourly means of Holter recorded heart rate. Tolerability. An open,
      randomised design with two parallel groups was employed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A pharmacokinetic and pharmacodynamic study comparing metoprolol IR and metoprolol CR/XL
      subsequent to initial treatment with intravenous and/or oral metoprolol in patients with
      suspected acut myocardial infarction
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2000</start_date>
  <completion_date type="Actual">April 2002</completion_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile in terms of Cmax, Cmin, AUC</measure>
    <time_frame>Treatment duration: 4 days</time_frame>
    <description>Assesment following multiple dosing of metoprolol CR/XL 200 mg once daily, or multiple dosing of metoprolol IR 200 mg daily in divided doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics in terms of Hourly means of heart rate (Holter recorded)</measure>
    <time_frame>Treatment duration: 4 days</time_frame>
    <description>Assesment following multiple dosing of metoprolol CR/XL 200 mg once daily, or multiple dosing of metoprolol IR 200 mg daily in divided doses</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety profile in terms of adverse events</measure>
    <time_frame>Treatment duration: 4 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Metoprolol- Toprol XL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metoprolol extended release (CR/XL) tablet 200 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metoprolol- Lopressor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoprolol immediate release (IR) tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol- Toprol XL</intervention_name>
    <description>Extended release tablet, 200mg once daily for 4 days</description>
    <arm_group_label>Metoprolol- Toprol XL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoprolol- Lopressor</intervention_name>
    <description>Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily</description>
    <arm_group_label>Metoprolol- Lopressor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients admitted to the CCU with suspected acute myocardial
             infarction

          -  Age 18 years or older

          -  Treated with and tolerated the full dose of metoprolol IR 50 mr four times daily or
             metoprolol CR/XL 200 mg once daily on study day 1

          -  Expected to stay in the CCU until the morning of study day 4

          -  Sinus rhythm on the day of admission and at randomisation

        Exclusion Criteria:

          -  Pregnancy or childbearing potential without adequate contraception

          -  Participation in a clinical study during the last 30 days or previous randomisation in
             the present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Elmfeldt, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca R&amp;D MÃ¶lndal</affiliation>
  </overall_official>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metoprolol, acute myocardial infarction, pharmacokinetics, pharmacodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metoprolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

